DUE: January 7, 2027
Funding available to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk
Grant Opportunity: Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics